Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33‐Positive Acute Myeloid Leukemia: A French Retrospective Observational Study
eJHaem · 2026-12 · 7 (6)
DOI: 10.1002/jha2.70454 ↗Kurz gefasst
Fachartikel in der Zeitschrift eJHaem, online erschienen am 14.11.2026. Verfasst von Juliette Lambert und 8 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Hématologie Clinique Centre Hospitalier de Versailles Le Chesnay France. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Introduction
Gemtuzumab ozogamicin (GO), a CD33‐targeted antibody–drug conjugate, is approved in combination with daunorubicin/cytarabine for patients ≥ 15 years with de novo, CD33‐positive acute myeloid leukemia (AML).
Methods
This retrospective, observational study assessed real‐world use, clinical outcomes, and safety of GO in 113 patients with de novo AML treated between 2014 and 2022 in the French authorization for temporary use (ATU) and post‐ATU program.
Results
During first induction, most patients (98.1%; 105/107) received GO with other agents, mainly daunorubicin/cytarabine (60.0%; 63/105). After 44.6 months’ median follow‐up (95% CI: 33.8–69.3), 78.6% (88/112) responded; 72.3% (81/112) achieved complete response, 52.2% (24/46) without measurable residual disease. Median (95% CI) event‐free survival (EFS), relapse‐free survival (RFS), and overall survival (OS) were 13.1 months (9.9–17.5), 17.5 months (12.6–35.6), and 49.8 months (21.8–not estimable), respectively. Overall, 46.9% of patients died. Older age predicted shorter OS ( p < 0.001). FLT3‐TKD mutation ( p = 0.013) and adverse cytogenetic classification ( p = 0.015) predicted shorter EFS. ECOG performance status ≥ 2 ( p = 0.005) and adverse cytogenetic classification ( p = 0.001) predicted shorter RFS. Forty‐four patients (38.9%) reported ≥ 1 adverse event of interest; 13.3% were serious and 26.6% treatment‐related; most commonly thrombocytopenia (21.2%). GO was predominantly administered per indication. No new safety signals were reported.
Conclusions
Results demonstrate real‐world safety and clinical outcomes of GO plus induction therapy for patients with de novo CD33‐positive AML. Trial Registration EU Post Authorization Study (PAS) register number: EUPAS44551
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Service d'Hématologie Clinique Centre Hospitalier de Versailles Le Chesnay France.
- Service d'Hématologie Clinique Hôpital Saint-Louis Institut De La Leucémie Paris France.
- Service d'Hématologie Clinique Centre Hospitalier Universitaire Amiens-Picardie Amiens France.
- Hematology Unit Avicenne Hospital University Sorbonne Paris Nord Bobigny France.
- Service d'Hématologie Clinique Hôpital Lyon Sud Pierre Bénite France.
- Hématologie Clinique Hôpital Simone Veil Troyes France.
ORCID-Profile: Cécile Pautas
Förderung
- Pfizer
Zitieren
APA
Lambert, J., Raffoux, E., Lebon, D., Braun, T., Heiblig, M., Santagostino, A., Vekhoff, A., Gogat-Marchant, K., & Pautas, C. (2026). Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33‐Positive Acute Myeloid Leukemia: A French Retrospective Observational Study. eJHaem, 7(6). https://doi.org/10.1002/jha2.70454
Vancouver
Lambert J, Raffoux E, Lebon D, Braun T, Heiblig M, Santagostino A, et al. Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33‐Positive Acute Myeloid Leukemia: A French Retrospective Observational Study. eJHaem. 2026;7(6). doi:10.1002/jha2.70454
BibTeX
@article{Lambert2026,
author = {Lambert, Juliette and Raffoux, Emmanuel and Lebon, Delphine and Braun, Thorsten and Heiblig, Maël and Santagostino, Alberto and Vekhoff, Anne and Gogat-Marchant, Karïn and Pautas, Cécile},
title = {Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33‐Positive Acute Myeloid Leukemia: A French Retrospective Observational Study},
journal = {eJHaem},
year = {2026},
volume = {7},
number = {6},
doi = {10.1002/jha2.70454}
}
EUVIMED